Typhoid fever is a major cause of morbidity and mortality in developing countries. This review assessed the efficacy, safety, and immunogenicity of the tetanus toxoid conjugate typhoid vaccine (Vi-TT) in children and adolescents. Randomized controlled trials involving Vi-TT in individuals under 18 were included. Eligible studies were screened, and quality was assessed using the Cochrane Risk of Bias-2 tool. Meta-analysis was conducted with RevMan Web. Four trials with 111 481 children found the risk of blood culture-confirmed typhoid fever after Vi-TT to be 0.18 compared with nontyphoid vaccines. Adverse event rates were similar, with a serious adverse event risk of 0.82 within six months. Seroconversion was 58.04 times higher at 28 days and 21.80 times higher after 18 months postvaccination, respectively). One trial had a high risk of bias, so sensitivity analysis was performed with and without it. GRADE assessment showed strong evidence that Vi-TT reduces typhoid risk without significant safety concerns. Seroconversion declined over time but remained significantly higher after 18 months. This concludes that Vi-TT is safe and effective for children and adolescents, and is recommended for vaccination in endemic areas.
BhanMBahlRBhatnagarS.Typhoid and paratyphoid fever. Lancet. 2005;366(9487):749-762.
2.
KarkeyAThompsonCNTranVuThieuN, et al. Differential epidemiology of Salmonella Typhi and Paratyphi A in Kathmandu, Nepal: a matched case control investigation in a highly endemic enteric fever setting. PLoS Negl Trop Dis. 2013;7(8):e2391.
3.
BhuniaRHutinYRamakrishnanRPalNSenTMurhekarM.A typhoid fever outbreak in a slum of South Dumdum municipality, West Bengal, India, 2007: evidence for foodborne and waterborne transmission. BMC Public Health. 2009;9:1-8.
4.
BhuttaZAGaffeyMFCrumpJA, et al. Typhoid fever: way forward. Am J Trop Med Hyg. 2018;99(suppl 3):89-96. doi:10.4269/ajtmh.180111
5.
BhuttaZACapedingMRBavdekarA, et al. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. Lancet Infect Dis. 2014;14(2):119-129. doi:10.1016/S1473-3099(13)70241-X
6.
GarrettDOLongleyATAiemjoyK, et al. Incidence of typhoid and paratyphoid fever in Bangladesh, Nepal, and Pakistan: results of the Surveillance for Enteric Fever in Asia Project. Lancet Glob Health. 2022;10(7):e978-e988.
CrumpJAMintzED. Global trends in typhoid and paratyphoid fever. Clin Infect Dis. 2010;50(2):241-246. doi:10.1086/649541
9.
StanawayJDReinerRCBlackerBF, et al. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis. 2019;19(4):369-381.
10.
ImJIslamMTAhmmedF, et al. Can existing improvements of water, sanitation, and hygiene (WASH) in urban slums reduce the burden of typhoid fever in these settings?Clin Infect Dis. 2021;72(11):e720-e726.
11.
KimCGoucherGTadesseBTLeeWAbbasKKimJH.Associations of water, sanitation, and hygiene with typhoid fever in case-control studies: a systematic review and meta-analysis. BMC Infect Dis. 2023;23(1):562.
12.
World Health Organization. Typhoid vaccines: WHO position paper, March 2018—recommendations. Vaccine. 2019;37(2):214-216.
13.
BinnsCLowWY.Vaccination: a modern public health miracle. Asia Pac J Public Health. 2022;34(4):329-330. doi:10.1177/10105395221094801
14.
SinghalLGuptaVGautamVKourI.XDR salmonella typhi warrants vaccine use in Asian pacific region: prevention is still better than cure. Asia Pac J Public Health. 2023;35(6-7):463-464.
International Vaccine Institute. SK bioscience’s typhoid conjugate vaccine achieves WHO prequalification. Accessed March 10, 2024. https://www.ivi.int/sk-bioscience
BatoolRQamarZHSalamRAYousafzaiMTAshornPQamarFN.Efficacy of typhoid vaccines against culture-confirmed Salmonella Typhi in typhoid endemic countries: a systematic review and meta-analysis. Lancet Glob Health. 2024;12(4):e589-e598.
19.
DashNRoseW.Typhoid conjugate vaccine: is it time for it to be in the national immunization schedule?Indian Pediatr. 2020;57(7):609-610.
20.
HigginsJPThomasJChandlerJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons; 2019.
BariliFParolariAKappeteinPAFreemantleN.Statistical primer: heterogeneity, random- or fixed-effects model analyses?Interact Cardiovasc Thorac Surg. 2018;27(3):317-321.
23.
QadriFKhanamFLiuX, et al. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. Lancet. 2021;398(10301):675-684. doi:10.1016/S0140-6736(21)01124-7
24.
HigginsJPEldridgeSLiT. Including variants on randomized trials. In: HigginsJPThomasJChandlerJ, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons; 2019:569-593.
25.
PageMJHigginsJPSterneJA. Assessing risk of bias due to missing results in a synthesis. In: HigginsJPThomasJChandlerJ, et al eds. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons; 2019:349-374.
26.
GuyattGHOxmanADMontoriV, et al. GRADE guidelines: 5. Rating the quality of evidence—publication bias. J Clin Epidemiol. 2011;64(12):1277-1282.
27.
BollandMJAvenellAGreyA.Analysis of cluster randomised trials as if they were individually randomised. Lancet Diabetes Endocrinol. 2023;11(2):75.
28.
ShakyaMColin-JonesRTheiss-NylandK, et al. Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal. N Engl J Med. 2019;381(23):2209-2218. doi:10.1056/NEJMoa1905047
29.
ShakyaMVoyseyMTheiss-NylandK, et al. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. Lancet Glob Health. 2021;9(11):e1561-e1568. doi:10.1016/S2214-109X(21)00346-6
30.
MitraMShahNGhoshAChatterjeeSKaurIBhattacharyaN.Efficacy and safety of Vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph) in Indian children: school-based cluster randomized study. Hum Vaccin Immunother. 2016;12:939-945. doi:10.1080/21645515.2015.1117715
31.
TadesseBTKhanamFAhmmedF, et al. Prevention of typhoid by Vi conjugate vaccine and achievable improvements in household water, sanitation, and hygiene: evidence from a cluster-randomized trial in Dhaka, Bangladesh. Clin Infect Dis. 2022;75(10):1681-1687. doi:10.1093/cid/ciac289
32.
KhanamFBabuGRahmanN, et al. Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh. Vaccine. 2023;41(19):3137-3140.
33.
KhanamFKimDRLiuX, et al. Assessment of vaccine herd protection in a cluster-randomised trial of Vi conjugate vaccine against typhoid fever: results of further analysis. EClinicalMedicine. 2023;58:101925.
34.
LiangYDriscollAJPatelPD, et al. Typhoid conjugate vaccine effectiveness in Malawi: evaluation of a test-negative design using randomised, controlled clinical trial data. Lancet Glob Health. 2023;11(1):e136-e144. doi:10.1016/S2214-109X(22)00466-1
35.
Nampota-NkombaNNyirendaOMKhondeL, et al. Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial. Lancet Glob Health. 2022;10(9):e1326-e1335. doi:10.1016/S2214-109X(22)00275-3
36.
PatelPDPatelPLiangY, et al. Safety and efficacy of a typhoid conjugate vaccine in Malawian children. N Engl J Med. 2021;385(12):1104-1115. doi:10.1056/NEJMoa2035916
37.
PatelPDLiangYMeiringJE, et al. Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children. Lancet. 2024;403(10425):459-468.
38.
VadrevuKMDugyalaRMahantashettiNS, et al. Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) and measles or measles-mumps-rubella vaccines in 8-9 months-old Indian children. Hum Vaccin Immunother. 2022;18(7):2150030. doi:10.1080/21645515.2022.2150030
39.
SirimaSBOuedraogoABarryN, et al. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: a randomized controlled phase 2 trial. Int J Infect Dis. 2021;108:465-472. doi:10.1016/j.ijid.2021.05.061
40.
LinFYHoVAKhiemHB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med. 2001;344(17):1263-1269. doi:10.1056/NEJM200104263441701
41.
CanhDGLinFYThiemVD, et al. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect Immun. 2004;72(11):6586-6588. doi:10.1128/IAI.72.11.6586-6588.2004
42.
JinCGibaniMMMooreM, et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017;390(10111):2472-2480. doi:10.1016/S0140-6736(17)32149-9
43.
SiddalingaiahNTuluvaSTuragaK.A multicentre single blind randomised controlled phase-II/III study to evaluate immunogenicity and safety of single intramuscular dose of biological e’s VI-capsular polysaccharide-CRM197 conjugate typhoid vaccine in healthy infants, children and adults in comparison with a licensed comparator. Indian Pediatr. 2020;87(11):982. doi:10.1007/s12098-020-03504-8
44.
KarimSYousafzaiMTKhaliqAQamarF.Adverse events following mass immunization with typhoid conjugate vaccine (Typbar TCV) at Hyderabad, Pakistan. Int J Infect Dis. 2020;101(suppl 1):470. doi:10.1016/j.ijid.2020.09.1231
45.
HoffmanSALeBoaCDateK, et al. Programmatic effectiveness of a pediatric typhoid conjugate vaccine campaign in Navi Mumbai, India. MedRxiv. 2022. doi:10.1093/cid/ciad132
46.
MohanVKVaranasiVSinghA, et al. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis. 2015;61(3):393-402. doi:10.1093/cid/civ295
47.
ThuluvaSParadkarVMaturRTuragaKGvSR.A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E’s Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine (TyphiBEV™) in healthy infants, children, and adults in comparison with a licensed comparator. Hum Vaccin Immunother. 2022;18(5):2043103. doi:10.1080/21645515.2022.2043103
48.
VoyseyMPollardAJ.Seroefficacy of Vi polysaccharide-tetanus toxoid typhoid conjugate vaccine (Typbar TCV). Clin Infect Dis. 2018;67(1):18-24. doi:10.1093/cid/cix1145
49.
KandulnaAKUttamKGSharmaS, et al. Long-term persistence of immunogenicity after primary vaccination and response to booster vaccination with typhoid conjugate vaccine: results of a phase IV extension study. Indian Pediatr. 2022;59(5):388-392.
50.
KunduRKandulnaAKNayakU, et al. Immunogenicity and safety of typhoid conjugate vaccine in healthy Indian subjects: a randomized, active-controlled, comparative clinical trial. Indian Pediatr. 2020;57:625-630.
51.
DeeksJJHigginsJPAltmanDG; Cochrane Statistical Methods Group. Analysing data and undertaking meta-analyses. In: HigginsJPThomasJChandlerJ, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons; 2019:241-284.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
